Discovery, biochemistry and biology of lovastatin.
Level 5 - mechanism / opinion, no new human data
Narrative review of drug discovery and biological mechanisms without primary empirical data
PubMed 3055919 · doi:10.1016/0002-9149(88)90002-1
What was done
This narrative review describes the biological rationale for targeting endogenous cholesterol synthesis, the identification of HMG-CoA reductase as the rate-limiting enzyme converting HMG-CoA to mevalonate, and the discovery of lovastatin from fungal metabolites. It reviews preclinical and clinical evidence regarding its mechanism of action and effects on cholesterol clearance.
What was found
The abstract provides no quantitative data or numerical outcomes. It reports qualitatively that lovastatin reduces cholesterol synthesis across cell culture, animal models, and humans. This inhibition leads to an increase in hepatic LDL receptor activity and a subsequent decrease in circulating total and low-density lipoprotein (LDL) cholesterol.
Why it matters
It outlines the foundational pharmacology of lovastatin, demonstrating how targeted inhibition of HMG-CoA reductase upregulates LDL receptors to clear circulating atherogenic lipoproteins.
Limits
The abstract provides no quantitative effect estimates, sample sizes, patient demographics, adverse event rates, or descriptions of clinical trial methodologies.
Cited by
- supports Statins lower LDL cholesterol predominantly by upregulating LDL receptor activity.